Exclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials

Sanofi has temporarily stopped recruiting new COVID-19 patients for two clinical trials on hydroxychloroquine and will no longer supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up, it said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news